OPB 101
Alternative Names: OPB-101Latest Information Update: 08 Nov 2024
Price :
$50 *
At a glance
- Originator Outpace Bio
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Ovarian cancer
Most Recent Events
- 08 Nov 2024 Pharmacodynamics data from the preclinical studies in Ovarian cancer released by Outpace Bio
- 05 Nov 2024 Outpace Bio plans a clinical trial for Fallopian tube cancer, Ovarian cancer, Peritoneal cancer (Late-stage disease) in 2025
- 05 Apr 2024 Pharmacodynamics data from the preclinical studies in Solid tumours presented at 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)